Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany.
Adult
Aged
Case-Control Studies
Diabetes Mellitus, Type 2
/ epidemiology
Female
Germany
/ epidemiology
Humans
Hyperthyroidism
/ complications
Hypothyroidism
/ complications
Incidence
Logistic Models
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ epidemiology
Obesity
/ epidemiology
Prevalence
Retrospective Studies
Risk Factors
Thyroiditis, Autoimmune
/ complications
Young Adult
disease burden
liver disease
metabolic comorbidities
non-alcoholic steatohepatitis
thyroid gland disorders
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
19
04
2021
accepted:
13
06
2021
pubmed:
22
7
2021
medline:
1
3
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
Studies investigating a potential association between hypothyroidism and non-alcoholic fatty liver disease (NAFLD) showed conflicting results and large-scale population-based data from Germany on this topic are currently missing. It was the aim of this analysis to investigate the impact of thyroid gland disorders on the prevalence of NAFLD in Germany. In this case-control study, using the German disease Analyzer database (IQVIA), NAFLD patients were matched to patients without NAFLD by age, sex, index year, treating physician, diabetes mellitus type II, and obesity. The main outcome of the study was an association between thyroid gland disorders (hypothyroidism, hyperthyroidism and autoimmune thyroiditis) and incident NAFLD and was evaluated using logistic regression analyses. 57,483 patients with NAFLD were matched to 57,483 patients without liver disease. Mean age of the cohort was 60.3 years (±14.1) and 52.3% were men. In regression analyses, hypothyroidism (OR 1.17, 95% CI 1.10 - 1.24, p < 0.001) as well as autoimmune thyroiditis (OR 1.53, 95% CI 1.35-1.73, p < 0.001) were associated with a higher risk of NAFLD. In contrast, hyperthyroidism was associated with a lower risk of NAFLD (OR 0.85, 95% CI 0.77-0.94, p < 0.001). The effect of hypothyroidism on the prevalence of NAFLD remained significant across men (OR 1.31, 95% CI 1.15-1.48) as well as women (OR 1.12, 95% CI 1.05-1.21). Hypothyroidism seems to be a risk factor for incident NAFLD.
Sections du résumé
BACKGROUND
Studies investigating a potential association between hypothyroidism and non-alcoholic fatty liver disease (NAFLD) showed conflicting results and large-scale population-based data from Germany on this topic are currently missing.
OBJECTIVE
It was the aim of this analysis to investigate the impact of thyroid gland disorders on the prevalence of NAFLD in Germany.
METHODS
In this case-control study, using the German disease Analyzer database (IQVIA), NAFLD patients were matched to patients without NAFLD by age, sex, index year, treating physician, diabetes mellitus type II, and obesity. The main outcome of the study was an association between thyroid gland disorders (hypothyroidism, hyperthyroidism and autoimmune thyroiditis) and incident NAFLD and was evaluated using logistic regression analyses.
RESULTS
57,483 patients with NAFLD were matched to 57,483 patients without liver disease. Mean age of the cohort was 60.3 years (±14.1) and 52.3% were men. In regression analyses, hypothyroidism (OR 1.17, 95% CI 1.10 - 1.24, p < 0.001) as well as autoimmune thyroiditis (OR 1.53, 95% CI 1.35-1.73, p < 0.001) were associated with a higher risk of NAFLD. In contrast, hyperthyroidism was associated with a lower risk of NAFLD (OR 0.85, 95% CI 0.77-0.94, p < 0.001). The effect of hypothyroidism on the prevalence of NAFLD remained significant across men (OR 1.31, 95% CI 1.15-1.48) as well as women (OR 1.12, 95% CI 1.05-1.21).
CONCLUSION
Hypothyroidism seems to be a risk factor for incident NAFLD.
Identifiants
pubmed: 34288580
doi: 10.1002/ueg2.12124
pmc: PMC8435260
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
829-836Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Références
United European Gastroenterol J. 2020 Oct;8(8):942-948
pubmed: 32698692
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Hepatol Commun. 2020 Jun 22;4(9):1293-1301
pubmed: 32923833
BMC Endocr Disord. 2020 Jul 6;20(1):100
pubmed: 32631284
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
Biochem Biophys Res Commun. 1990 Nov 15;172(3):1150-6
pubmed: 2123100
Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724
pubmed: 33559592
Endocr Rev. 2020 Jan 1;41(1):
pubmed: 31629366
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2591-5
pubmed: 6264482
J Intern Med. 2015 Mar;277(3):331-342
pubmed: 24754313
Liver Int. 2021 Jun;41(6):1227-1242
pubmed: 33590598
United European Gastroenterol J. 2021 Sep;9(7):829-836
pubmed: 34288580
J Lipid Res. 1993 Jun;34(6):961-70
pubmed: 8354961
Med Clin (Barc). 2020 Jan 10;154(1):1-6
pubmed: 31153607
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):377-379
pubmed: 32514153
Hepatology. 2021 Jul;74(1):474-482
pubmed: 33486773
Hepatology. 2019 Mar;69(3):934-936
pubmed: 30515858
FASEB J. 2008 Aug;22(8):2981-9
pubmed: 18434432
Lancet. 2019 Nov 30;394(10213):2012-2024
pubmed: 31727409
Exp Clin Endocrinol Diabetes. 2022 Mar;130(3):172-177
pubmed: 33601426
Biochem Pharmacol. 1998 Jul 1;56(1):121-9
pubmed: 9698096
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76
pubmed: 23855299
Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116
pubmed: 30288767
Int J Endocrinol. 2016;2016:5083746
pubmed: 27143968
Front Endocrinol (Lausanne). 2017 Nov 29;8:335
pubmed: 29238323
Curr Opin Lipidol. 2011 Dec;22(6):479-88
pubmed: 22002020
Proc Natl Acad Sci U S A. 1973 Dec;70(12):3839-42
pubmed: 4521209
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10297-302
pubmed: 16006512
Biochem J. 2003 Feb 1;369(Pt 3):687-95
pubmed: 12435272
Dig Dis Sci. 2020 Jul;65(7):2112-2119
pubmed: 31797186
Clin Transl Gastroenterol. 2019 Aug;10(8):e00066
pubmed: 31397685
Hepatology. 2012 Nov;56(5):1828-37
pubmed: 22829162